Nierenzellkarzinom

详细信息    查看全文

• 作者：Dr. M.A. Reiter F.E.B.U ; M. Kurosch ; A. Haferkamp
• 关键词：Nierenzellkarzinom ; Medikament?se Therapie ; Targettherapeutika ; Prognostische Modelle ; Metastasierung ; Renal cell carcinoma ; Drug therapy ; Targeted therapies ; Prognostic models ; Neoplasm metastasis
• 刊名：Der Urologe A
• 出版年：2015
• 出版时间：May 2015
• 年：2015
• 卷：54
• 期：5
• 页码：735-748
• 全文大小：590 KB
• 参考文献：1.Ferlay J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374-403View Article PubMed <br>2.Kim SP et al (2011) Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort. J Urol 185(6):2035-039View Article PubMed <br>3.Parkin DM et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74-08View Article PubMed <br>4.Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353(23):2477-490View Article PubMed <br>5.Brehmer B et al (2012) Metastasectomy for renal cell cancer. Urologe A 51(9)1202-208<br>6.Abern MR et al (2014) Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. Anticancer Res 34(5):2405-411PubMed <br>7.Pichler M et al (2013) Comparison of the 2002 and 2010 TNM classification systems regarding outcome prediction in clear cell and papillary renal cell carcinoma. Histopathology 62(2):237-46View Article PubMed <br>8.Kim HL et al (2004) Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. J Urol 171(5):1810-813View Article PubMed <br>9.Bensalah K et al (2006) Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 175(3 Pt 1):859-63View Article PubMed <br>10.Leibovich BC et al (2010) Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 183(4):1309-315View Article PubMed <br>11.Flanigan RC, Polcari AJ, Hugen CM (2011) Prognostic variables and nomograms for renal cell carcinoma. Int J Urol 18(1):20-1View Article PubMed <br>12.Hartmann A et al (2014) Prognostic and predictive molecular markers for urologic cancers. Urologe A 53(4):491-00View Article PubMed <br>13.Motzer RJ et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1):289-96View Article PubMed <br>14.Mekhail TM et al (2005) Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23(4):832-41View Article PubMed <br>15.Heng DY et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794-799View Article PubMed <br>16.Heng DY et al (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14(2):141-48View Article PubMed Central PubMed <br>17.Stadler WM et al (2003) Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 170(4 Pt 1):1141-145View Article PubMed <br>18.Gore ME et al (2010) Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 375(9715):641-48View Article PubMed Central PubMed <br>19.Coppin C et al (2000) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 3:CD001425PubMed <br>20.Coppin C et al (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 1:CD001425PubMed <br>21.Motzer RJ et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1):289-96View Article PubMed <br>22.Escudier B et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103-111View Article PubMed <br>23.Fyfe G et al (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13(3):688-96PubMed <br>24.Fisher RI, Rosenberg SA, Fyfe G (2000) Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6(Suppl 1):S55–S57PubMed <br>25.McDermott DF et al (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23(1):133-41View Article PubMed <br>26.Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373(9669):1119-132View Article PubMed <br>27.Motzer RJ et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115-24View Article PubMed <br>28.Motzer RJ et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcin
• 作者单位：Dr. M.A. Reiter F.E.B.U (1) <br> M. Kurosch (1) <br> A. Haferkamp (1) <br><br>1. Klinik für Urologie und Kinderurologie, Universit?tsklinikum Frankfurt, Johann Wolfgang Goethe-Universit?t, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Deutschland <br>
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health<br>Urology and Andrology<br>
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-0563

文摘

Renal cell carcinoma (RCC) represents the sixth-leading cancer-specific cause of death worldwide. This is mainly caused by metastatic or locally advanced RCC. Approximately 25-0- of patients present with metastasis during the initial diagnosis. Furthermore, 20-0- of patients develop metastatic disease following initial curative surgery. Metastatic RCC is characterized by a poor prognosis with a median overall survival of less than -?years. Today, targeted therapies such as VEGF receptor inhibitors and antagonists as well as mTOR inhibitors represent the standard of care in metastatic RCC. Conventional chemotherapies or cytokine-based medications have been abandoned due to inferior clinical efficacy compared with targeted therapies. In Germany, sunitinib, pazopanib, temsirolimus, and bevacizumab have been approved for first-line treatment and sorafenib, axitinib, and everolimus for second-line treatment. Prognostic models, assessing individual risk profiles, have been developed in the last 15?years, which are crucial for the design of trials, patient counseling, and initiation of goal-directed therapies.